Sepracor has submitted a New Drug Application to the US Food and DrugAdministration for approval to market levalbuterol HCl inhalation solution, a single-isomer formulation of racemic albuterol, for the treatment of asthma.
The NDA comprises data from nine studies involving 502 asthmatics and 42 healthy volunteers. In one four-week, 362-patient study, levalbuterol was shown to have a greater improvement in lung function than racemic albuterol after the first dose. Over the study period, levalbuterol (1.25mg and 0.625mg) had equivalent or greater changes in forced expiratory volume, compared with 2.5mg of albuterol.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze